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PCLINICAL RESEARCH Clinical Trial
Does Microvolt T-Wave
Alternans Testing Predict Ventricular
Tachyarrhythmias in Patients With Ischemic
Cardiomyopathy and Prophylactic Defibrillators?
The MASTER (Microvolt T Wave Alternans Testing
for Risk Stratification of Post-Myocardial Infarction Patients) Trial
Theodore Chow, MD, FACC,* Dean J. Kereiakes, MD, FACC,* John Onufer, MD,†
Alan Woelfel, MD,‡ Sinan Gursoy, MD,§ Brett J. Peterson, BS, Mark L. Brown, PHD,
Wenji Pu, PHD, David G. Benditt, MD,¶ on behalf of the MASTER Trial Investigators
Cincinnati, Ohio; Chesapeake, Virginia; Grand Rapids, Michigan; Naples, Florida; and Minneapolis, Minnesota
Objectives The purpose of this trial was to determine whether microvolt T-wave alternans (MTWA) predicts ventricular tachy-
arrhythmic events (VTEs) in post-myocardial infarction patients with left ventricular ejection fraction (LVEF)30%.
Background Previous studies have established MTWA as a predictor for total and arrhythmic mortality, but its ability to identify
prophylactic implantable cardioverter-defibrillator (ICD) recipients most likely to experience VTEs remains uncertain.
Methods This prospective trial was conducted at 50 U.S. centers. Patients were eligible if they met MADIT-II (Multicenter Auto-
matic Defibrillator Implantation Trial II) indications for device implant. All patients underwent MTWA testing followed
by ICD implantation, with pre-specified programming to minimize the likelihood of therapies for non–life-threatening
VTE. Minimum follow-up was 2 years with annual MTWA testing. Initially indeterminate MTWA tests were repeated.
Results Analyses were conducted on 575 patients (84%male; average age SD 65 11 years; average LVEF SD 0.24
0.05). The final distribution of MTWA results were: MTWA positive in 293 (51%), MTWA negative in 214 (37%), and indeter-
minate in 68 patients (12%). Over an average follow-up of 2.1 0.9 years, there were 70 VTEs. A VTE occurred in 48 of
361 (13%, 6.3%/year) MTWA non-negative and 22 of 214 (10%, 5.0%/year) MTWA negative patients. A non-negative
MTWA test result was not associated with VTE (hazard ratio: 1.26; 95% confidence interval: 0.76 to 2.09; p 0.37), al-
though total mortality was significantly increased (hazard ratio: 2.04; 95% confidence interval: 1.10 to 3.78; p 0.02).
Conclusions In MADIT-II–indicated ICD-treated patients, the risk of VTE does not differ according to MTWA classification, despite
differences in total mortality. (MASTER I–Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients;
NCT00305240) (J Am Coll Cardiol 2008;52:1607–15) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.018a
c
c
r
o
i
f
p
f
f
s
t
w
nespite increased deployment of implantable cardioverter-
efibrillators (ICDs) guided by prospective clinical trial data
1–4), prevention of sudden cardiac death (SCD) remains
rom *The Lindner Clinical Trial Center at The Christ Hospital, Cincinnati, Ohio;
Cardiovascular Associates, Ltd., Chesapeake, Virginia; ‡West Michigan Heart,
rand Rapids, Michigan; §Naples Community Hospital, Naples, Florida;
Medtronic, Inc., Minneapolis, Minnesota; and the ¶University of Minnesota,
inneapolis, Minnesota. This study was sponsored by Medtronic, Inc. Dr. Chow has
eceived honoraria from Biotronik, Cambridge Heart, Medtronic, Inc., and St. Jude
edical, and has ownership interest in Medtronic, Inc. Dr. Onufer has received
onoraria from St. Jude Medical. Mr. Peterson is employed by Medtronic, Inc. Dr.
rown has ownership interest in and is employed by Medtronic, Inc. Dr. Pu has
wnership interest in and is employed by Medtronic, Inc. Dr. Benditt has ownership
nterest in, has received honoraria from, and is on the consultant/advisory board for
edtronic, Inc. and St. Jude Medical.t
Manuscript received March 5, 2008; revised manuscript received August 8, 2008,
ccepted August 11, 2008.n unmet challenge. From a public health perspective, SCD
ontinues to be the leading source of mortality in developed
ountries, with approximately 310,000 annual deaths occur-
ing in the U.S. (5). At the same time, the economic burden
f broad ICD deployment is substantial (6). Therefore,
dentification of high-risk patients most likely to benefit
rom ICD implantation is of significant clinical and health
olicy interest. Whereas current device implant guidelines
ocus on patients with reduced left ventricular ejection
raction (LVEF) (30% to 35%), this approach lacks
pecificity for SCD. In principle, improved risk stratification
echniques could more accurately identify high-risk patients
ho would benefit from ICD therapy, thereby reducing the
umber of unnecessary ICD implantations and diminishing
he financial burden to the health care system.
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The MASTER Trial Results November 11, 2008:1607–15Measurement of microvolt
T-wave alternans (MTWA) dur-
ing controlled heart rate elevation
has emerged as a potentially useful
predictor of ventricular arrhythmic
events and mortality (7), including
in post-myocardial infarction pa-
tients (8) and those with ischemic
cardiomyopathy (9) or congestive
heart failure (CHF) (10).Whether
application of MTWA can further
improve risk stratification in pa-
tients with low LVEF who are
currently considered candidates for
prophylactic ICD therapy is un-
clear. Specifically, MTWA might
identify a subgroup of this patient
population at sufficiently low risk
of SCD in which ICD therapy
might be withheld. The MAS-
TER (Microvolt T Wave Alter-
nans Testing for Risk Stratifica-
ion of Post MI Patients) trial was a prospective, multicenter,
ndustry-supported (Medtronic Inc., Minneapolis, Minnesota)
rial conducted in the U.S. in which patients meeting
MADIT-II” indication for ICD treatment (11) underwent
TWA testing before device implantation. This trial primar-
ly recruited ambulatory outpatients from within private prac-
ices. The primary objective was to determine whether
TWA testing predicted subsequent development of ventric-
lar tachyarrhythmic events (VTEs).
ethods
atient recruitment. The MASTER trial was conducted
y 50 participating U.S. investigator centers (82% private
ractice, 18% academic medical center). The protocol was
pproved by an institutional review board for each partici-
ating center. Patient recruitment, data acquisition, and
ollow-up were the responsibility of the local investigators
nd overseen by MASTER trial personnel. All data were
ent to the central data analysis and coordinating center
Medtronic Cardiac Rhythm Disease Management Clinical
esearch Department), which was responsible for review,
rocessing, and analysis of data as well as coordination with
he independent Clinical Events Committee and MTWA
eading core laboratory (Massachusetts Institute of Tech-
ology, Division of Health Sciences and Technology). The
rst patient was enrolled in October 2003, with completion
f follow-up in February 2007 and database closure in May
007.
Patients were candidates for enrollment if they had a
rior myocardial infarction, LVEF 30%, were 18 years
ld, and were able to give informed consent. Trial exclusions
ncluded: atrial fibrillation or flutter at time of enrollment,
Abbreviations
and Acronyms
CHF  congestive heart
failure
CI  confidence interval
CRT  cardiac
resynchronization therapy
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
MTWA  microvolt T-wave
alternans
NYHA  New York Heart
Association
SCD  sudden cardiac
death
VTE  ventricular
tachyarrhythmic eventocumented sustained or symptomatic ventricular tachyar- ehythmia (including a history of cardiac arrest), myocardial
nfarction within the past month, revascularization proce-
ure (surgical or percutaneous) within the past 3 months,
iagnostic electrophysiology study or MTWA test within
he past year, class IV CHF, advanced cerebrovascular
isease, life expectancy of 1 year, inability to perform
TWA testing, or contraindication to ICD implantation.
Baseline patient demographic, clinical, and medication
ata were acquired upon trial enrollment.
TWA testing. Baseline MTWA testing was required for
ll enrolled patients. Treadmill was the only method of
xercise testing used. For patients unable to exercise, other
ethods were used, including dobutamine infusion and
ardiac pacing. All sites were required to use either the
H2000 or HearTwave system (Cambridge Heart Inc.,
edford, Massachusetts) for MTWA testing. All sites were
rained and certified by a Cambridge Heart Inc. represen-
ative before enrollment of patients.
Standard criteria were applied to MTWA interpreta-
ion (12). In brief, a test was considered positive if 1.9
V of alternans was recorded in either 1 orthogonal lead
r 2 contiguous pre-cordial leads with an onset heart rate
f 110 beats/min during a 2-min recording period that
as free from significant artifacts. A test was considered
egative if the aforementioned criteria were not met with
maximum negative heart rate of 105 beats/min. All
ther successfully completed tests were considered inde-
erminate—generally a result of excessive electrode noise,
nability to achieve target heart rate, frequent ectopic
eats, or other artifacts.
The protocol required that all indeterminate MTWA
ests be repeated. If the repeat MTWA test yielded a
eterminate result (positive or negative), the determinate
esult was used for trial analysis. A new MTWA test
lassification called “technically inadequate” was established
o denote any test in which either the MTWA data were
ot acquired (e.g., “leads off” indicated by the machine) or
he initial classification was indeterminate and the test was
ot repeated (unless medical justification was supplied).
echnically inadequate tests were excluded from analysis.
ll MTWA tests were over-read by a core laboratory
linded to patient characteristics. The core laboratory clas-
ification was considered final.
In accordance with common practice, the protocol spec-
fied combining positive and indeterminate outcome pa-
ients into a single MTWA “non-negative” group that was
ompared against MTWA negatives for primary trial out-
ome analysis. This approach has been validated by studies
howing equivalent outcomes among MTWA positives and
ndeterminates (9). The MASTER protocol additionally
equired follow-up MTWA testing every 12 months after
nrollment until trial completion. Repetition of initially
ndeterminate MTWA tests was required for baseline and
ollow-up MTWA testing. For consistency, sites were
ncouraged to use the same method of heart rate elevation
(
f
D
w
a
p
S
v
t
t
(
d
3
i
d
o
p
p
a
f
p
a
T
w
y
a
r
t
d
v
V
d
t
c
i
t
d
o
e
S
h
g
V
t
w
C
t
t
c
n
K
m
M
9
u
a
d
N
s
R
B
w
c
d
a
a
p
a
o
7
T
t
a
h
f
e
T
l
b
T
0
V
n
n
r
K
t
m
o
A
e
t
a
g
C
s
9
O
h
a
a
(
l
q
p
w
1609JACC Vol. 52, No. 20, 2008 Chow et al.
November 11, 2008:1607–15 The MASTER Trial Resultse.g., exercise, cardiac pacing, or pharmacologic) on the
ollow-up tests as was used for the baseline test.
evice implantation and programming. In accordance
ith practice guidelines, clinically indicated market-
pproved Medtronic ICDs were to be subsequently im-
lanted in all patients enrolled in the MASTER trial.
ingle-chamber, dual-chamber, and resynchronization de-
ices were all allowable.
To minimize the likelihood of therapies for non–life-
hreatening ventricular arrhythmias, the protocol required
he following device programming: ventricular fibrillation
VF) detection interval: 320 ms; VF number of intervals to
etect: 24 of 32; ventricular tachycardia detection interval:
70 ms (monitor only); ventricular tachycardia number of
ntervals to detect: 16; supraventricular tachycardia (SVT)
iscriminators “on;” SVT limit: 300 ms with high-rate time
ut disabled; maximum output shocks across all VF thera-
ies; and pre-storage electrogram “on.” Antitachycardia
acing therapies were not permitted. Deviations from the
forementioned programming required medical justification
rom the participating site. The proportion of patients
rogrammed according to protocol specifications was 88%
t baseline and 95% by the 6-month follow-up visit.
rial follow-up and end point determination. Patients
ere followed at 6-month intervals for a minimum of 2
ears and up to 4 years or until trial closure. Device, clinical,
nd medication data were reviewed and updated during
outine trial visits. In addition, patient diaries were supplied
o facilitate patient recall of symptoms and correlation with
evice-recorded arrhythmias. Hospital stays or clinician
isits for any end point events were noted.
The primary end point for the MASTER trial was a
TE, defined as: 1) SCD; or 2) an appropriate ICD
ischarge by a device programmed in accordance with the
rial protocol. All ventricular tachyarrhythmic episodes re-
orded by the devices and deaths were adjudicated by an
ndependent Clinical Events Committee physician blinded
o patient characteristics and MTWA test results. SCD was
efined as a cardiac death within 1 h of onset of symptoms
r occurring during sleep in the absence of a more plausible
xplanation.
tatistical analyses. The trial was designed to detect a
azard ratio (HR) of 3 between the MTWA non-negative
roup and the MTWA negative group. A minimum of 57
TEs were required to achieve at least 80% power with a
ype I error of 0.05. All statistical analyses were performed
ith SAS (version 9.1, SAS Institute Inc., Cary, North
arolina). Baseline characteristics between MTWA nega-
ive and non-negative groups were compared with Student
tests for continuous variables and chi-square tests for
ategorical variables. Survival curves between the MTWA
egative and non-negative groups were constructed with
aplan-Meier estimates (13). Cox proportional hazards
odels (14) were used to assess the relationship between
TWA testing and VTE and to estimate the HRs and
5% confidence intervals (CIs). Cox regression analysis was Esed to adjust for pre-specified potential confounding vari-
bles, which included: age, gender, LVEF, beta-blocker
rugs, positive inotropic agents, QRS duration, race, and
ew York Heart Association (NYHA) functional class. All
tatistical tests were 2-sided and used an alpha level of 0.05.
esults
aseline characteristics. The trial enrolled 654 patients, of
hom 44 were later found to have met study exclusion
riteria and 35 did not have a valid baseline MTWA test (21
efined as technically inadequate according to the protocol
nd 14 not performed). The remaining 575 patients used for
nalyses consisted of 361 (63%) MTWA non-negative
atients (293 [51%] positive and 68 [12%] indeterminate)
nd 214 (37%) MTWA negative patients. The distribution
f testing modality was 78% exercise, 10% pharmacological,
% atrial pacing, and 5% atrioventricular sequential pacing.
able 1 provides the baseline characteristics of MASTER
rial patients. The population was, on average, 65 years old
nd 84% male with a mean LVEF of 24%. In addition, 50%
ad a QRS duration 120 ms, and 71% had NYHA
unctional class II to III CHF. Some significant differences
xisted between MTWA negative and non-negative groups.
he MTWA non-negative patients were significantly older,
ess frequently Caucasian, less likely to be taking beta-
locker drugs, and had wider QRS durations.
rial outcomes. There were 70 VTEs over a mean of 2.1
.9 years (7 SCDs and 63 appropriate device therapies). A
TE occurred in 48 MTWA non-negative and 22 MTWA
egative patients. The annual event rates for MTWA
on-negative and negative patients were 6.3% and 5.0%,
espectively (HR: 1.26; 95% CI: 0.76 to 2.09; p  0.37).
aplan-Meier event-free survival curves for VTE according
o MTWA classification are shown in Figure 1. After
ultivariate adjustment, MTWA remained nonpredictive
f VTE (HR: 1.16; 95% CI: 0.68 to 1.99; p  0.58).
lthough tests classified as technically inadequate were
xcluded from analysis, inclusion of these patients within
he MTWA non-negative cohort did not alter this result.
Additional outcomes measures were explored in second-
ry analysis (Table 2). Total mortality was significantly
reater in MTWA non-negative patients (HR: 2.04; 95%
I: 1.10 to 3.78; p 0.02) (Fig. 2), a finding that remained
tatistically robust after multivariate adjustment (HR: 2.16;
5% CI: 1.13 to 4.12; p  0.02).
ther predictors of VTE. Univariate Cox proportional
azards analysis was used to evaluate other potential vari-
bles for VTE prediction. Beta-blocker treatment was
ssociated with a significantly decreased frequency of VTE
HR: 0.54; CI: 0.30 to 0.96; p  0.04), whereas spirono-
actone treatment was associated with an increased fre-
uency of this end point (HR: 1.68; 95% CI: 1.00 to 2.80;
 0.048). The LVEF was also significantly associated
ith VTE (HR: 0.95; 95% CI: 0.90 to 0.99; p  0.02).
ach 1% decline in LVEF was associated with a 5% relative
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The MASTER Trial Results November 11, 2008:1607–15ncrease in VTE. There was borderline evidence for in-
reased VTE among patients with QRS duration 120 ms
HR: 1.64; 95% CI: 0.99 to 2.68; p  0.05).
ubgroup analyses. The predictive value of MTWA test-
ng for VTE was evaluated in patient subgroups including
VEF, QRS duration, beta-blocker usage, cardiac resyn-
hronization therapy (CRT), MTWA testing modality, and
YHA functional class (Table 3). The possibility of signif-
cant interactions (p  0.05) between MTWA and sub-
roup variables was evaluated, but none were found. The
TWA prediction did not achieve statistical significance
ithin any subgroup; however, MTWA nearly achieved
ignificant association for VTE within narrow QRS dura-
ion (120 ms) patients (HR: 2.30; 95% CI: 0.92 to 5.76;
 0.08). Finally, restricting primary end point analysis to
aseline Characteristics
Table 1 Baseline Characteristics
Characteristics All (n  575) MTWA Neg
Age, yrs 65 11
Gender, % male 84
Race, % white 89
LVEF, % 24.0 4.8 24
QRS 120 ms, % 50
LBBB† 36
RBBB† 18
IVCD† 25
QRS measurement (ms) 119 30 1
CHF, % 73
History of atrial fibrillation, % 18
CABG, % 55
PCI, % 52
Diabetes, % 35
Hypertension, % 68
Syncope, % 12
Device type, %
Single-chamber 37
Dual-chamber 40
CRT 23
NYHA functional class, %
I 15
II 44
III 27
No HF 15
Medications, %
Aspirin 78
ACE 64
ARB 19
Beta-blocker 87
Statin 78
Digoxin 23
Diuretic 62
Spirolonactone 21
Class I antiarrhythmic 0.2
Class III antiarrhythmic 7
t tests used for continuous variables and chi-square tests for categorical variables. †Percentage
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; CABG coronary a
VCD  intraventricular conduction delay; LBBB  left bundle branch block; LVEF  left ventricu
ercutaneous coronary intervention; RBBB  right bundle branch block.hose patients who had MTWA testing with the exercise fodality did not change the study outcome (HR: 1.14; 95%
I: 0.65 to 2.02).
ndeterminate MTWA tests. The indeterminacy rate af-
er the initial MTWA test was 19%. The predominant
auses of indeterminacy for the 107 patients initially classi-
ed with an indeterminate test result were: inability to
chieve target HR in 32 (30%), frequent ectopic beats in 22
21%), electrode noise in 15 (14%), and nonsustained
lternans in 36 (34%). Of the 107 patients that were initially
lassified as indeterminate, repeat MTWA testing was
erformed for 69 patients, yielding a baseline determinate
esult for 41 (59%). Patient safety concerns precluded repeat
esting for 38 patients. Two patients had an initial techni-
ally inadequate test that was reclassified as indeterminate
n the basis of repeat testing. The causes of indeterminacy
(n  214) MTWA Non-Negative (n  361) p Value*
1 66 10 0.006
86 0.12
86 0.004
.5 23.8 4.9 0.11
55 0.01
34 0.21
19 0.45
25 0.69
0 121 29 0.02
72 0.51
17 0.61
57 0.28
50 0.20
36 0.65
70 0.12
11 0.44
0.34
35
41
25
0.57
14
42
27
17
78 0.99
65 0.99
18 0.49
86 0.01
76 0.24
25 0.11
63 0.28
19 0.17
0.3 0.44
7 0.99
d from 285 patients with QRS duration 120 ms.
pass graft; CHF congestive heart failure; CRT cardiac resynchronization therapy (device type);
tion fraction; MTWA  microvolt T-wave alternans; NYHA  New York Heart Association; PCI ative
63 1
81
94
.4 4
44
42
15
23
15 3
74
19
52
55
34
64
14
41
37
22
15
46
26
13
78
64
20
92
81
20
59
23
0
7
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November 11, 2008:1607–15 The MASTER Trial Resultsn indeterminate baseline MTWA test were: failure to
each adequate heart rate in 18 (26%), frequent ectopy in 18
26%), excessive noise in 25 (37%), RR interval alternans in
(9%), and unsustained T-wave alternans in 1 (1%). The
R for VTE when comparing only MTWA positives
ersus negatives was 1.24 (95% CI: 0.73 to 2.08; p  0.43)
nd remained nonsignificant after multivariate adjustment.
able 4 depicts comparisons between individual MTWA
ohorts and VTE occurrence. There were no significant
ifferences in VTE between individual MTWA groups.
After initiation of the MASTER trial, a retrospective
nalysis of the T-Wave Alternans in Heart Failure Study
oncluded that more accurate MTWA classification is
chieved by considering as abnormal only those indetermi-
ates that are due to patient-related factors, including
xcessive ectopy, inability to reach target HR, or nonsus-
ained alternans (15). Using this modified MTWA classi-
cation algorithm had little effect on the univariate HR
stimate for VTE (HR: 1.34; 95% CI: 0.80 to 2.25;
 0.27).
Figure 1 Kaplan-Meier Survival Curves for VTE Free Survival
MTWA  microvolt T-wave alternans; VTE  ventricular tachyarrhythmic event (prim
rial Outcome Events
Table 2 Trial Outcome Events
Outcomes, n (%) MTWA Negative (n  214) M
First VTE 22 (10.3)
Appropriate device therapy 20 (90.9)
Sudden cardiac death 2 (9.1)
Total mortality 13 (6.1)
Sudden cardiac 3 (23.1)
Nonsudden cardiac 5 (38.5)
Noncardiac 3 (23.1)
Unknown 2 (15.4)p values are based on Wald’s test with estimates from the Cox proportional hazard models.
CI  confidence interval; HR  hazard ratio; MTWA  microvolt T-wave alternans; VTE  ventricular tiscussion
he objective of the MASTER trial was to determine
hether MTWA predicts VTE in post-myocardial infarc-
ion patients with LVEF 30%. Over an average follow-up
f 2.1 years, there was no observed correlation between
TWA result and VTE. Specifically, the VTE rate was not
ignificantly lower in the MTWA negative group than in
he MTWA non-negative group. Additionally, Kaplan-
eier analysis showed no divergence in this end point
etween MTWA groups at any time during the trial.
ecause enrolled patients were to receive ICDs by design,
0% of end point events were appropriate ICD therapies
nd 10% were sudden deaths. Therefore, the MASTER
rial demonstrates that MTWA testing does not identify
ADIT-II–indicated patients more (or less) likely to re-
eive appropriate ICD therapies.
The MASTER trial is among the largest prospective
valuations to date of MTWA in MADIT-II–like patients.
ther strengths include uniform treatment with ICDs and
d point).
on-Negative (n  361) Unadjusted HR (95% CI) p Value*
48 (13.3) 1.26 (0.76–2.09) 0.37
43 (89.6) 1.24 (0.73–2.11) 0.42
5 (10.4) 1.44 (0.28–7.44) 0.66
46 (12.7) 2.04 (1.10–3.78) 0.02
7 (15.2) 1.35 (0.35–5.23) 0.66
17 (37.0) 1.96 (0.72–5.31) 0.19
15 (32.6) 2.88 (0.83–9.94) 0.10
7 (15.2) 2.02 (0.42–9.72) 0.38ary enTWA Nachyarrhythmic event (primary end point).
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The MASTER Trial Results November 11, 2008:1607–15tandardization of device programming to minimize shocks
or nonlethal arrhythmias. In addition, our MTWA inde-
erminacy rate of 12% is among the lowest reported and was
chieved through repeat testing of initially indeterminate
ests. Many prior studies of MTWA testing in MADIT-II–
16,17) or SCD-HeFT–like post-myocardial infarction pa-
ients (9,18) have had significant limitations, including: few
nrolling centers (9,18), small study size (16,17), retrospec-
ive design (17), lack of standardized ICD treatment or
evice programming (9,16–18), and higher indeterminacy
ates (9,16–18). The MASTER trial overcomes these
imitations and is among the most carefully controlled
rospective MTWA trials.
The MASTER trial’s findings are consistent with some
ecent prospective studies of MTWA testing in low-LVEF
atients, including the SCD-HeFT (Sudden Cardiac Death
n Heart Failure Trial) MTWA substudy (19) and the
ARISMA (Cardiac Arrhythmias and Risk Stratification
fter Myocardial Infarction) study (20). Additional recent
tudies that were technically “positive” for MTWA predic-
ion at the same time suggested potential limitations of this
echnique, namely: 1) MTWA prediction might be limited
o 1 year (21); 2) residual arrhythmic risk in MTWA
ormals might still be substantial (22); and 3) MTWA
rediction might be reduced in patients with LVEF 30%
23). In contrast, the aforementioned studies have all
ncluded a large percentage of ICD-treated patients and
sed device-treated or recorded arrhythmias as end points.
ence, the nonspecificity of device end points for arrhyth-
ic death could potentially influence study results by
verestimating true SCD events, including in MTWA
ormal patients. This argument would seem to be supported
y the observation that studies with relatively few ICD-
Figure 2 Kaplan-Meier Survival Curves for Total Mortality
MTWA  microvolt T-wave alternans.reated patients (10,16,24) or ICD shock end points (9) or tn which total mortality was the primary end point (9,10,16)
ave generally shown MTWA to be a significant predictor
f events. The presence of the ICD could also mask
ssociation of MTWA with VTE if it facilitates electrical
nstability through cardiac pacing. However, although
evice-triggered ventricular arrhythmias do occur, they are
ncommon (1%) and thus unlikely to have influenced the
esults of the MASTER trial (25).
The MASTER trial showed that MTWA was a signif-
cant predictor of total mortality (HR: 2), even within a
opulation uniformly treated with ICDs and where 80% of
eaths were not sudden cardiac. This HR is similar to the
ne presented in a study by Chow et al. (9) of ischemic
CD-HeFT type patients (HR: 2.2) but less robust than
hat reported by Bloomfield et al. (16) of MADIT-II–type
atients (HR: 4.8). It seems that some of this excess
ortality could be mediated through association of a non-
egative MTWA test result with established high-risk
linical features. The MTWA non-negative patients were
lder (66 vs. 63 years), had wider QRS durations (121 vs.
15 ms), lower beta-blocker exposure (86% vs. 92%), and
ere less likely to be Caucasian (86% vs. 94%). Although in
heory CRT therapy could have influenced results through
odifying end point risk after MTWA testing, we did not
etect any significant statistical interaction between
TWA prediction and CRT, and prescription of CRT
herapy was balanced between MTWA cohorts (Table 1). It
s also an intriguing possibility that a non-negative MTWA
est might indicate true physiological conditions (e.g., isch-
mia, CHF, electrolyte disturbances, medication effects)
hat could impact total mortality independent from ventric-
lar arrhythmia.
According to study protocol, MTWA positives and inde-erminates were combined to form a single “non-negative”
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November 11, 2008:1607–15 The MASTER Trial Resultsroup. This methodology is reflective of common practice and
s supported by a large study showing equivalent outcomes
mong MTWA positives and indeterminates (9). However,
uring the enrollment period of the MASTER trial, Kaufman
t al. (15) published a study suggesting that “patient-related”
auses of indeterminacy (excessive ectopy, inability to reach
arget HR, nonsustained alternans) should be classified as
TWA positive, and “test-related” causes of indeterminacy
electrode noise) should be classified as “technically inadequate”
nd removed from analysis. Therefore, as a secondary analysis
e evaluated the MASTER trial data with this modified
TWA classification algorithm and found that it made no
ifference to study results. It is worth emphasizing that the
mpact of this classification algorithm was lessened because the
verall indeterminacy rate in theMASTER trial was only 12%.
A previous study suggested that MTWA testing might be
onfounded by bundle branch block (26). Although statis-
ical testing for interaction between MTWA prediction and
undle branch block was not significant (p  0.10), the
ross correlation of MTWA with VTE in narrow QRS
TWA Prediction for VTE Within Subgroups
Table 3 MTWA Prediction for VTE Within Subgroups
n Events
Unadjusted HR
(95% CI) p Value*
LVEF, % 0.71
25 227 32 1.13 (0.55–2.35)
25 348 38 1.39 (0.69–2.81)
QRS duration, ms 0.10
120 285 43 0.85 (0.45–1.58)
120 270 25 2.30 (0.92–5.76)
Beta-blocker 0.87
Yes 502 56 1.21 (0.70–2.10)
No 72 14 1.08 (0.30–3.88)
CRT 0.24
Yes 119 15 0.73 (0.26–2.04)
No 456 55 1.47 (0.82–2.63)
MTWA modality† 0.48
Exercise 447 53 1.14 (0.65–2.02)
Nonexercise 127 17 1.83 (0.60–5.60)
NYHA functional class 0.41
III 153 24 0.81 (0.36–1.81)
II 251 24 1.64 (0.68–3.96)
II 171 22 1.57 (0.58–4.26)
p value for testing the equality of HRs is from Wald’s test of interaction between MTWA and each
ariable with Cox proportional hazard models. †Exercise tests were done with treadmills. Nonex-
rcise test modalities included pharmacological (n  56), atrial pacing (n  42), and atrioventric-
lar sequential pacing (n  29).
Abbreviations as in Tables 1 and 2.
omparison of VTE Between MTWA Positive, Negative, and Indeter
Table 4 Comparison of VTE Between MTWA Positive, Negative
Unadjusted HR (95% CI)
Positive versus negative 1.24 (0.73–2.08)
Indeterminate versus positive 1.13 (0.54–2.30)
Indeterminate versus negative 1.17 (0.80–1.73)
p values are based on Wald’s test with estimates from the Cox proportional hazard models. Variab
nd NYHA functional class.
Abbreviations as in Tables 1 and 2.uration patients was better (HR: 2.30) than in wide QRS
uration patients (HR: 0.85) (Table 3). Although this
nding is intriguing, this trial was not powered for subgroup
nalysis.
Another interesting finding in the MASTER trial is the
ow annual event rates—4.9% total mortality and 5.2%
ppropriate ICD discharge rate. By comparison, the
ADIT-II trial (2), around which our enrollment criteria
ere based, reported annual mortality and shock rates of
.5% and 14.1%, respectively, for patients randomized to
CD (although ICD programming was not protocol-
pecified in that study). Our event rates were more compa-
able to the SCD-HeFT trial (1), which reported annual
ortality and shock rates of 5.8% and 5.1%, respectively.
he qualifying LVEF for SCD-HeFT was 35% compared
ith 30% for MASTER and MADIT-II. We believe the
ifference in the ICD therapy rate between MASTER and
ADIT-II can be explained in large part by the strict ICD
rogramming criteria that was applied to our protocol. The
eason for the difference in total mortality between these
tudies, though, is less clear. Potential explanations include
se of higher output devices in MASTER versus MADIT-
I; differences in risk profile of patients recruited from
rivate practice (the majority in MASTER) compared with
cademic hospitals and heart failure clinics; or that, being a
ecent trial, the reservoir of high-risk patients has been
iminished by several years of broad-based prophylactic
evice implantation. Importantly, as in all MTWA stud-
es, there is likely enrollment bias toward patients with
ood exercise capacity and exclusion of those with a
istory of atrial fibrillation, both factors known to influ-
nce total and arrhythmic mortality. Finally, the higher use
f beta-blocker drugs in our study (87% vs. 70%) could account
or some of the difference in event rates. Not only were
eta-blocker drugs an independent predictor of freedom from
TE in the MASTER trial, but they have also been shown to
uppress MTWA (27). Finally, although the MASTER trial
ound no association for MTWA predicting the primary end
oint given sufficient power to detect an HR of3, we cannot
xclude the presence of a lesser and potentially clinically
elevant association.
The MASTER trial confirmed LVEF to be an important
redictor for arrhythmic events. Each 1% decrease in LVEF
esulted in a 5% relative increase in the hazard of VTE.
owever, the substantial differences in total mortality between
ASTER, MADIT-II, and SCD-HeFT ICD-treated pa-
te Groups
Indeterminate Groups
p Value* Adjusted HR (95% CI) p Value*
0.43 1.08 (0.62–1.87) 0.80
0.77 1.11 (0.53–2.34) 0.78
0.42 1.22 (0.80–1.86) 0.36
d for adjusted Cox models: age, gender, LVEF, beta-blocker, positive inotropes, QRS duration, race,mina
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The MASTER Trial Results November 11, 2008:1607–15ients despite similar mean LVEFs (24%, 23%, and 25%,
espectively) illustrates the limitations of LVEF alone as a risk
tratifier and the need to develop more specific predictors for
rrhythmic death. Reductions in SCD attributable to ICD
reatment inMADIT andMUSTT (Multicenter Unsustained
achycardia Trial), in which device implant was guided by
lectrophysiology study and Holter monitor, were approxi-
ately 2 times higher than in the MADIT-II and SCD-
eFT trials in which risk stratification (other than ejection
raction) was not used (1–4). However, the MASTER trial
esults demonstrate that more studies need to be done to
nderstand the role of MTWA in risk stratification for ICD
andidacy and, more generally speaking, the relationship be-
ween ICD shocks and lethal events. Future investigation
ight include the combination of MTWA with other risk
tratifiers within a “suite of predictors” approach and exploring
ew ICD indications within higher LVEF populations. The
atter is supported by a recent study that found MTWA
esting to be highly predictive within post-myocardial
nfarction patients having LVEF 40% (HR: 20) (28).
tudy limitations. The main limitation of this trial is the
se of ICD treatment for ventricular tachycardia/ventricular
brillation as a surrogate for SCD. An analysis of the
EFINITE (Defibrillators in Non-ischemic Cardiomyop-
thy Treatment Evaluation) trial by Ellenbogen et al. (29)
howed that ICD shocks overestimated arrhythmic mortal-
ty by a factor of 2. Because this limitation is inherent to any
CD trial and because we deemed it unethical to withhold
CD therapy in otherwise indicated patients, we instead
ddressed this issue through requiring that ICD therapies
e delivered only for VTEs that were fast (188 beats/min)
nd relatively long-lasting (24 beats). Although this
hould increase the specificity of therapies for arrhythmic
ortality, it is likely that ICD therapies will still overesti-
ate this end point by some (unknown) degree. It is
ossible that lack of specificity of ICD therapies for lethal
rrhythmias could mask a true relationship of MTWA with
rrhythmic mortality; thus the findings might not be appli-
able to a non–ICD-treated population.
In addition, combining different modalities of MTWA
esting (exercise, drug infusion, pacing) could be a limitation
f the predictive accuracy of these modalities is not equiva-
ent. However, the majority of patients in the MASTER
rial were tested with the same modality (treadmill exercise),
nd study results were not affected by restricting primary
utcome analysis to this subset of patients.
Although every effort was made to establish rhythm truth
or tachycardia episodes detected by ICDs, this cannot be
nown with absolute certainty—more so for single-chamber
CDs in which there is no atrial electrogram to guide
iagnosis.
onclusions
he MASTER trial showed that, within community private
ractice, MTWA testing in MADIT-II–indicated ICD-
1reated patients does not predict subsequent VTEs, al-
hough MTWA non-negative patients had significantly
igher mortality compared with MTWA negative patients.
eprint requests and correspondence: Dr. Theodore Chow,
irector of Electrophysiology Research, Lindner Center at The
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APPENDIX
or a list of persons and institutions who participated
n the MASTER trial, please see the online version of this article.
